Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: A study in isogenic resistant tumor cells

Breast Cancer Research

Volumn 14, Issue 1, 2012, Pages

  Sprowl, Jason A ^a,b   Reed, Kerry ^a   Armstrong, Stephen R ^c   Lanner, Carita ^b,c   Guo, Baoqing ^a   Kalatskaya, Irina ^d   Stein, Lincoln ^d   Hembruff, Stacey L ^a   Tam, Adam ^a   Parissenti, Amadeo M ^a,b,c,e  

^a SUDBURY REGIONAL HOSPITAL   (Canada)

^b LAURENTIAN UNIVERSITY   (Canada)

^c NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; I KAPPA B; PACLITAXEL; SN 50; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; ANTINEOPLASTIC AGENT; CYCLOHEXIMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN SYNTHESIS INHIBITOR; TAXOID;

ARTICLE; CELL STRAIN MCF 7; CLONOGENIC ASSAY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METABOLISM; OVARY TUMOR; PROTEIN DEGRADATION; SECRETION (PROCESS); TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL SURVIVAL; CYCLOHEXIMIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MCF-7 CELLS; NF-KAPPA B; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN SYNTHESIS INHIBITORS; PROTEOLYSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIGNAL TRANSDUCTION; TAXOIDS; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855458812     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3083     Document Type: Article

References (81)

1. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999, 35:1194-1201. 10.1016/S0959-8049(99)00122-7, 10615229.
2. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
3. Tannock IF, de WR, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512. 10.1056/NEJMoa040720, 15470213.
4. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral FS, Majlis A, Assadourian S, Van CE. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005, 23:5660-5667. 10.1200/JCO.2005.17.376, 16110025.
5. Posner MR. Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs 2001, 12(Suppl 1):S21-S24.
6. Iaffaioli RV, Tortoriello A, Santangelo M, Turitto G, Libutti M, Benassai G, Frattolillo A, Ciccarelli PD, De RP, Crovella F, Carbone I, Barbarisi A. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer. Clin Oncol (R Coll Radiol) 2000, 12:251-255.
7. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991, 83:288-291. 10.1093/jnci/83.4.288, 1671606.
8. Chazard M, Pellae-Cosset B, Garet F, Soares JA, Lucidi B, Lavail Y, Lenaz L. Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes. Bull Cancer 1994, 81:173-181.
9. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997, 57:229-233.
10. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001, 61:3369-3372.
11. Tong AW, Seamour B, Lawson JM, Ordonez G, Vukelja S, Hyman W, Richards D, Stein L, Maples PB, Nemunaitis J. Cellular immune profile of patients with advanced cancer before and after taxane treatment. Am J Clin Oncol 2000, 23:463-472. 10.1097/00000421-200010000-00007, 11039505.
12. Bogdan C, Ding A. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol 1992, 52:119-121.
13. Meloni F. Tumor necrosis factor alpha. Biological aspects. G Ital Chemioter 1989, 36:29-37.
14. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733. 10.1038/385729a0, 9034190.
15. MacEwan DJ. TNF ligands and receptors--a matter of life and death. Br J Pharmacol 2002, 135:855-875. 10.1038/sj.bjp.0704549, 1573213, 11861313.
16. Grell M, Zimmermann G, Hulser D, Pfizenmaier K, Scheurich P. TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways. J Immunol 1994, 153:1963-1972.
17. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995, 81:495-504. 10.1016/0092-8674(95)90070-5, 7758105.
18. Declercq W, Denecker G, Fiers W, Vandenabeele P. Cooperation of both TNF receptors in inducing apoptosis: involvement of the TNF receptor-associated factor binding domain of the TNF receptor 75. J Immunol 1998, 161:390-399.
19. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993, 74:845-853. 10.1016/0092-8674(93)90464-2, 8397073.
20. Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994, 78:681-692. 10.1016/0092-8674(94)90532-0, 8069916.
21. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY, Martin C. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999, 17:1786-1793.
22. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005, 11:298-305.
23. Hembruff SL, Laberge ML, Villeneuve DJ, Guo B, Veitch Z, Cecchetto M, Parissenti AM. Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance. BMC Cancer 2008, 8:318. 10.1186/1471-2407-8-318, 2596802, 18980695.
24. Guo B, Villeneuve DJ, Hembruff SL, Kirwan AF, Blais DE, Bonin M, Parissenti AM. Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat 2004, 85:31-51. 10.1023/B:BREA.0000021046.29834.12, 15039596.
25. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995, 270:14255-14258. 10.1074/jbc.270.24.14255, 7782278.
26. Hembruff SL, Villeneuve DJ, Parissenti AM. The optimization of quantitative reverse transcription PCR for verification of cDNA microarray data. Anal Biochem 2005, 345:237-249. 10.1016/j.ab.2005.07.014, 16139235.
27. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001, 29:365-371. 10.1038/ng1201-365, 11726920.
28. Eisenhart C. The assumptions underlying the analysis of variance. Biometrics 1947, 3:1-21. 10.2307/3001534, 20240414.
29. Tamhane AC, Dunlop DD. Statistics and Data Analysis from Elementary to Intermediate. 2000, 473-4. Englewood Cliffs, NJ:Prentice Hall, 1.
30. Sprowl JA, Armstrong SR, Lanner CM, Guo B, Reed K, Hembruff SL, Kalatskaya I, Stein L, Parissenti AM. Alterations in tumour necrosis factor signaling pathways associated with cytotoxicity and resistance to taxanes in tumour cells. Gene Expression Omnibus Database 2010, National Center For Biotechnology Information., http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=hrkztqqskcgsmpu&acc=GSE26129
31. Wu G, Feng X, Stein L. A human functional protein interaction network and its application to cancer data analysis. Genome Biol 2010, 11:R53. 10.1186/gb-2010-11-5-r53, 2898064, 20482850.
32. Gross JL, Yellen J. Graph Theory and Its Applications. 1998, Boca Raton, FL:, CRC Press, 1.
33. Enright AJ, Van DS, Ouzounis CA. An efficient algorithm for large-scale detection of protein families. Nucleic Acids Res 2002, 30:1575-1584. 10.1093/nar/30.7.1575, 101833, 11917018.
34. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13:2498-2504. 10.1101/gr.1239303, 403769, 14597658.
35. Udalova IA, Knight JC, Vidal V, Nedospasov SA, Kwiatkowski D. Complex NF-kappaB interactions at the distal tumor necrosis factor promoter region in human monocytes. J Biol Chem 1998, 273:21178-21186. 10.1074/jbc.273.33.21178, 9694874.
36. Moos PJ, Fitzpatrick FA. Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits. Cell Growth Differ 1998, 9:687-697.
37. Manthey CL, Qureshi N, Stutz PL, Vogel SN. Lipopolysaccharide antagonists block taxol-induced signaling in murine macrophages. J Exp Med 1993, 178:695-702. 10.1084/jem.178.2.695, 2191120, 8101863.
38. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999, 36:99-114. 10.2165/00003088-199936020-00002, 10092957.
39. Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K, Ting JP. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol 2000, 164:2769-2775.
40. Cai Z, Capoulade C, Moyret-Lalle C, mor-Gueret M, Feunteun J, Larsen AK, Paillerets BB, Chouaib S. Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function. Oncogene 1997, 15:2817-2826. 10.1038/sj.onc.1201445, 9419972.
41. Jackman RW, Rhoads MG, Cornwell E, Kandarian SC. Microtubule-mediated NF-kappaB activation in the TNF-alpha signaling pathway. Exp Cell Res 2009, 315:3242-3249. 10.1016/j.yexcr.2009.08.020, 3131200, 19732770.
42. Reed K, Hembruff SL, Laberge ML, Villeneuve DJ, Cote GB, Parissenti AM. Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells. Epigenetics 2008, 3:270-280. 10.4161/epi.3.5.6868, 19001875.
43. Evans CP. Serum levels of pro-inflammatory cytokines immediately increase two days after application of docetaxel in patients with castration-resistant prostate cancer and correlate with apoptosis and clinical response. 26th Annual Meeting of the Suropean Association of Urology, Vienna, Austria 2011,
44. Koti M, Vidal R, Nuin P, Haslehurst A, Weberpals J, Childs T, Bryson P, Feilloter HE, Squire J, Park PC. Identification of biomarkers of chemoresistance in serous epithelial ovarian cancer using integrative molecular profiling. American Association for Cancer Research 102nd Annual Meeting 2011, Abstract 11-A-6026-AACR Orlando, FL.
45. Montagut C, Tusquets I, Ferrer B, Corominas JM, Bellosillo B, Campas C, Suarez M, Fabregat X, Campo E, Gascon P, Serrano S, Fernandez PL, Rovira A, Albanell J. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 2006, 13:607-616. 10.1677/erc.1.01171, 16728586.
46. Stoelcker B, Ruhland B, Hehlgans T, Bluethmann H, Luther T, Mannel DN. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol 2000, 156:1171-1176. 10.1016/S0002-9440(10)64986-3, 1876893, 10751341.
47. Schroder CP, de ML, Westermann AM, Smit WM, Creemers GJ, de GH, Stouthard JM, van DG, Erjavec Z, van BA, Vader W, Willemse PH. Weekly docetaxel in metastatic breast cancer patients: No superior benefits compared to three-weekly docetaxel. Eur J Cancer 2011, 47:1355-62. 10.1016/j.ejca.2010.12.018, 21251813.
48. Aouizerat BE, Dodd M, Lee K, West C, Paul SM, Cooper BA, Wara W, Swift P, Dunn LB, Miaskowski C. Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue. Biol Res Nurs 2009, 11:27-41. 10.1177/1099800409333871, 19419979.
49. Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, Guttridge D, Rhoades C, Shah M, Criswell T, Caligiuri MA, Villalona-Calero MA. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006, 24:1852-1859. 10.1200/JCO.2005.04.2838, 16622259.
50. Yoo GH, Piechocki MP, Ensley JF, Nguyen T, Oliver J, Meng H, Kewson D, Shibuya TY, Lonardo F, Tainsky MA. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin Cancer Res 2002, 8:3910-3921.
51. Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol 2005, 55:277-285. 10.1007/s00280-004-0878-y, 15565326.
52. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005, 104:682-691. 10.1002/cncr.21227, 15986399.
53. van der Holt B, Lowenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, Ossenkoppele GJ, Verhoef GE, Ferrant A, Crump M, Selleslag D, Theobald M, Fey MF, Vellenga E, Dugan M, Sonneveld P. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005, 106:2646-2654. 10.1182/blood-2005-04-1395, 15994288.
54. Gupta S. A decision between life and death during TNF-alpha-induced signaling. J Clin Immunol 2002, 22:185-194. 10.1023/A:1016089607548, 12148593.
55. Karin M, Gallagher E. TNFR signaling: ubiquitin-conjugated TRAFfic signals control stop-and-go for MAPK signaling complexes. Immunol Rev 2009, 228:225-240. 10.1111/j.1600-065X.2008.00755.x, 19290931.
56. gli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997, 7:813-820. 10.1016/S1074-7613(00)80399-4, 9430226.
57. Hashimoto T, Schlessinger D, Cui CY. Troy binding to lymphotoxin-alpha activates NF kappa B mediated transcription. Cell Cycle 2008, 7:106-111. 10.4161/cc.7.1.5135, 18202551.
58. Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem 1997, 272:14029-14032. 10.1074/jbc.272.22.14029, 9162022.
59. Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, Gan Y, Cho YH, Garcia AD, Gollatz E, Dimke D, LaFleur D, Migone TS, Nardelli B, Wei P, Ruben SM, Ullrich SJ, Olsen HS, Kanakaraj P, Moore PA, Baker KP. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000, 275:35478-35485. 10.1074/jbc.M005224200, 10956646.
60. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, Farahani R, McLean M, Ikeda JE, MacKenzie A, Korneluk RG. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996, 379:349-353. 10.1038/379349a0, 8552191.
61. Scharf S, Hippenstiel S, Flieger A, Suttorp N, N'guessan PD. Induction of human {beta}-Defensin-2 in pulmonary epithelial cells by Legionella pneumophila: Involvement of TLR2 and TLR5, p38 MAPK, JNK, NF-{kappa}B and AP-1. Am J Physiol Lung Cell Mol Physiol 2010, 298:L687-L695. 10.1152/ajplung.00365.2009, 20154223.
62. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003, 424:797-801. 10.1038/nature01811, 12917690.
63. Chen G, Rong M, Luo D. TNFRSF6B neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell. Pathol Res Pract 2010, 206:631-641. 10.1016/j.prp.2010.05.011, 20591579.
64. Li X, Commane M, Nie H, Hua X, Chatterjee-Kishore M, Wald D, Haag M, Stark GR. Act1, an NF-kappa B-activating protein. Proc Natl Acad Sci USA 2000, 97:10489-10493. 27051, 10962024.
65. Rachner TD, Benad P, Rauner M, Goettsch C, Singh SK, Schoppet M, Hofbauer LC. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem 2009, 108:106-116. 10.1002/jcb.22232, 19544400.
66. Bertin J, Wang L, Guo Y, Jacobson MD, Poyet JL, Srinivasula SM, Merriam S, DiStefano PS, Alnemri ES. CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B. J Biol Chem 2001, 276:11877-11882. 10.1074/jbc.M010512200, 11278692.
67. Lye E, Mirtsos C, Suzuki N, Suzuki S, Yeh WC. The role of interleukin 1 receptor-associated kinase-4 (IRAK-4) kinase activity in IRAK-4-mediated signaling. J Biol Chem 2004, 279:40653-40658. 10.1074/jbc.M402666200, 15292196.
68. Xu Y, Tao X, Shen B, Horng T, Medzhitov R, Manley JL, Tong L. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature 2000, 408:111-115. 10.1038/35040600, 11081518.
69. Liao W, Xiao Q, Tchikov V, Fujita K, Yang W, Wincovitch S, Garfield S, Conze D, El-Deiry WS, Schutze S, Srinivasula SM. CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates TNF-induced NF-kappaB activation. Curr Biol 2008, 18:641-649. 10.1016/j.cub.2008.04.017, 2587165, 18450452.
70. Clarke CJ, Truong TG, Hannun YA. Role for neutral sphingomyelinase-2 in tumor necrosis factor alpha-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM) in lung epithelial cells: p38 MAPK is an upstream regulator of nSMase2. J Biol Chem 2007, 282:1384-1396.
71. Rockel JS, Kudirka JC, Guzi AJ, Bernier SM. Regulation of Sox9 activity by crosstalk with nuclear factor-kappaB and retinoic acid receptors. Arthritis Res Ther 2008, 10:R3. 10.1186/ar2349, 2374456, 18182117.
72. Liu TL, Shimada H, Ochiai T, Shiratori T, Lin SE, Kitagawa M, Harigaya K, Maki M, Oka M, Abe T, Takiguchi M, Hiwasa T. Enhancement of chemosensitivity toward peplomycin by calpastatin-stabilized NF-kappaB p65 in esophageal carcinoma cells: possible involvement of Fas/Fas-L synergism. Apoptosis 2006, 11:1025-1037. 10.1007/s10495-006-6353-y, 16547594.
73. Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, bdul-Rauf M, Price H, Karran L, Majekodunmi O, Wlodarska I, Pan L, Crook T, Hamoudi R, Isaacson PG, Dyer MJ. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999, 96:35-45. 10.1016/S0092-8674(00)80957-5, 9989495.
74. Peng C, Cho YY, Zhu F, Xu YM, Wen W, Ma WY, Bode AM, Dong Z. RSK2 mediates NF-{kappa}B activity through the phosphorylation of IkappaBalpha in the TNF-R1 pathway. FASEB J 2010, 24:3490-3499. 10.1096/fj.09-151290, 2923348, 20385620.
75. Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, Melnik LI, Alam J, McLachlan JA, Jaffe BM, Beckman BS, Burow ME. Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 2002, 132:293-301. 10.1067/msy.2002.125389, 12219026.
76. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, Gaestel M. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999, 1:94-97. 10.1038/10061, 10559880.
77. Walczak H, gli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997, 16:5386-5397. 10.1093/emboj/16.17.5386, 1170170, 9311998.
78. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008, 133:693-703. 10.1016/j.cell.2008.03.036, 18485876.
79. Ahmad M, Srinivasula SM, Wang L, Talanian RV, Litwack G, Fernandes-Alnemri T, Alnemri ES. CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP. Cancer Res 1997, 57:615-619.
80. Tsitsikov EN, Laouini D, Dunn IF, Sannikova TY, Davidson L, Alt FW, Geha RS. TRAF1 is a negative regulator of TNF signaling. enhanced TNF signaling in TRAF1-deficient mice. Immunity 2001, 15:647-657. 10.1016/S1074-7613(01)00207-2, 11672546.
81. Rowlett RM, Chrestensen CA, Nyce M, Harp MG, Pelo JW, Cominelli F, Ernst PB, Pizarro TT, Sturgill TW, Worthington MT. MNK kinases regulate multiple TLR pathways and innate proinflammatory cytokines in macrophages. Am J Physiol Gastrointest Liver Physiol 2008, 294:G452-G459.